مباشر

Endpoints NewsHealth groups say HHS is trying to 'rush reinstatement' of ACIP Endpoints NewsB cell therapy maker Be Bio stops hemophilia trial Clinical OMICsFibroblast Signaling Pathways Linked to Angiogenesis Differences in NSCLC Endpoints NewsFDA raises no major red flags with Moderna's flu shot FierceBiotechEli Lilly’s M&A spree continues with acquisition of non-opioid pain drugmaker 4E FierceBiotechAmenable FDA review bodes well for Moderna's mRNA flu shot ahead of adcomm grilling Clinical OMICsMini Brains Help Identify Treatment for Rare Form Parkinson’s Disease Endpoints NewsFDA greenlights Colorado's drug import proposal CellThe critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM FierceBiotechPE firm Altaris scoops up AI drug development outfit Simulations Plus for $375M BioPharma DiveLilly buys non-opioid pain drugmaker 4E BioPharma DiveExpress Scripts, PCMA sue to block Tennesee law breaking up PBMs and pharmacies

BioWorld ١٦ يونيو ٢٠٢٦

Chinese challenger Gan & Lee gains momentum in metabolic disease

Chinese diabetes specialist Gan & Lee Pharmaceuticals is strengthening its position in metabolic disease after reporting positive phase III data for both once-w...

Chinese diabetes specialist Gan & Lee Pharmaceuticals is strengthening its position in metabolic disease after reporting positive phase III data for both once-weekly basal insulin candidate Ludefen and obesity therapy bofanglutide.